Maxcyte (MXCT) Common Equity (2020 - 2026)

Maxcyte (MXCT) has reported Common Equity for 7 consecutive years, with $158.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 16.76% year-over-year to $158.8 million in Q2 2026; TTM through Jun 2026 was $158.8 million, a 16.76% decrease from a year earlier, with the FY2025 full-year figure at $171.5 million, down 16.85% from the prior year.
• Common Equity was $158.8 million for Q2 2026 at Maxcyte, down from $167.9 million in the prior quarter.
• Over five years, Common Equity peaked at $262.2 million in Q1 2022 and troughed at $158.8 million in Q2 2026.
• A 5-year average of $217.7 million and a median of $223.8 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 226.34% in 2022 and decreased 16.85% in 2025, its largest moves.
• Over 5 years, Common Equity stood at $254.0 million in 2022, then slipped by 8.58% to $232.2 million in 2023, then declined by 11.16% to $206.3 million in 2024, then declined by 16.85% to $171.5 million in 2025, then dropped by 7.43% to $158.8 million in 2026.
• The last three Common Equity figures came in at $158.8 million (Q2 2026), $167.9 million (Q1 2026), and $171.5 million (Q4 2025), per Business Quant data.